Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free ARQT Stock Alerts

Arcutis Biotherapeutics (ARQT) Competitors

Arcutis Biotherapeutics logo
$25.34 -1.12 (-4.22%)
Closing price 09/18/2026 03:59 PM Eastern
Extended Trading
$25.50 +0.16 (+0.62%)
As of 09/18/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ARQT vs. CORT, ELAN, AXSM, RDY, and CRNX

Should you buy Arcutis Biotherapeutics stock or one of its competitors? Arcutis Biotherapeutics's main competitors and comparable companies include Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Arcutis Biotherapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Corcept Therapeutics presently has a consensus target price of $138.17, suggesting a potential upside of 25.28%. Arcutis Biotherapeutics has a consensus target price of $35.57, suggesting a potential upside of 40.35%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Arcutis Biotherapeutics
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

Corcept Therapeutics has a net margin of 6.52% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics6.52% 8.26% 6.45%
Arcutis Biotherapeutics 6.15%15.05%6.51%

Corcept Therapeutics has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M15.66$99.65M$0.42262.60
Arcutis Biotherapeutics$376.07M8.47-$16.14M$0.21120.69

In the previous week, Corcept Therapeutics had 22 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 28 mentions for Corcept Therapeutics and 6 mentions for Arcutis Biotherapeutics. Corcept Therapeutics' average media sentiment score of 0.73 beat Arcutis Biotherapeutics' score of 0.46 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
9 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Arcutis Biotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Corcept Therapeutics beats Arcutis Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Arcutis Biotherapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Elanco Animal Health's net margin of -3.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Elanco Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics6.15% 15.05% 6.51%
Elanco Animal Health -3.96%8.13%3.99%

Arcutis Biotherapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$376.07M8.47-$16.14M$0.21120.69
Elanco Animal Health$4.72B2.37-$232M-$0.41N/A

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 40.35%. Elanco Animal Health has a consensus price target of $29.09, indicating a potential upside of 29.92%. Given Arcutis Biotherapeutics' higher possible upside, equities analysts clearly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

In the previous week, Elanco Animal Health had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 10 mentions for Elanco Animal Health and 6 mentions for Arcutis Biotherapeutics. Elanco Animal Health's average media sentiment score of 0.66 beat Arcutis Biotherapeutics' score of 0.46 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elanco Animal Health
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Arcutis Biotherapeutics beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Axsome Therapeutics' net margin of -24.68%. Arcutis Biotherapeutics' return on equity of 15.05% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-24.68% -265.55% -28.10%
Arcutis Biotherapeutics 6.15%15.05%6.51%

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arcutis Biotherapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M17.05-$183.17M-$3.75N/A
Arcutis Biotherapeutics$376.07M8.47-$16.14M$0.21120.69

In the previous week, Axsome Therapeutics had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 10 mentions for Axsome Therapeutics and 6 mentions for Arcutis Biotherapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Arcutis Biotherapeutics' score of 0.46 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcutis Biotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Axsome Therapeutics currently has a consensus price target of $267.60, suggesting a potential upside of 28.79%. Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 40.35%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.91
Arcutis Biotherapeutics
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

Axsome Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Axsome Therapeutics beats Arcutis Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Arcutis Biotherapeutics currently has a consensus target price of $35.57, suggesting a potential upside of 40.35%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Arcutis Biotherapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics6.15% 15.05% 6.51%
Dr. Reddy's Laboratories 10.15%9.49%6.32%

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 5 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.53 beat Arcutis Biotherapeutics' score of 0.46 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dr. Reddy's Laboratories
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Arcutis Biotherapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$376.07M8.47-$16.14M$0.21120.69
Dr. Reddy's Laboratories$3.58B2.84$456M$0.4427.71

Summary

Arcutis Biotherapeutics beats Dr. Reddy's Laboratories on 10 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Crinetics Pharmaceuticals?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Arcutis Biotherapeutics' return on equity of 15.05% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics6.15% 15.05% 6.51%
Crinetics Pharmaceuticals -1,189.88%-44.22%-39.77%

Arcutis Biotherapeutics presently has a consensus price target of $35.57, suggesting a potential upside of 40.35%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.65%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arcutis Biotherapeutics is more favorable than Crinetics Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67
Crinetics Pharmaceuticals
1 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.24

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$376.07M8.47-$16.14M$0.21120.69
Crinetics Pharmaceuticals$7.70M1,170.54-$465.32M-$5.04N/A

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 0 mentions for Crinetics Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.46 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Arcutis Biotherapeutics Neutral
Crinetics Pharmaceuticals Neutral

Arcutis Biotherapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Crinetics Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARQT vs. The Competition

Export
MetricArcutis BiotherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.33B$12.54B$7.26B$13.13B
Dividend YieldN/A2.63%2.56%12.94%
P/E Ratio120.69792.21273.8025.39
Price / Sales8.47945.09692.79108.43
Price / CashN/A88.4477.4251.66
Price / Book16.3510.4910.456.33
Net Income-$16.14M$2.81B$3.48B$358.24M
7 Day Performance6.09%2.81%0.88%1.17%
1 Month Performance-4.22%2.47%-1.58%-2.59%
1 Year Performance45.82%3.95%18.09%5.97%

Arcutis Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARQT
Arcutis Biotherapeutics
3.6216 of 5 stars		$25.34
-4.2%		$35.57
+40.4%		+43.1%$3.33B$376.07M120.69354
CORT
Corcept Therapeutics
4.0159 of 5 stars		$112.93
+1.0%		$138.17
+22.3%		+38.2%$12.24B$761.41M269.64730
ELAN
Elanco Animal Health
4.1521 of 5 stars		$23.09
+1.0%		$29.09
+26.0%		+17.1%$11.56B$4.72BN/A9,400
AXSM
Axsome Therapeutics
3.7947 of 5 stars		$212.06
+3.9%		$267.60
+26.2%		+75.1%$11.14B$638.50MN/A925
RDY
Dr. Reddy's Laboratories
1.6764 of 5 stars		$12.20
+4.5%		N/A-17.7%$10.16B$3.58B27.6727,527

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 9/19/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel